Do Statins Raise Triglycerides? Why Levels Can Be High

Statins lower triglycerides, not raise them. Every major class of statin reduces triglyceride levels to some degree, and clinical trials have consistently confirmed this effect. Yet plenty of people taking a statin see triglyceride numbers on their lab work that remain stubbornly high or even climb over time. The explanation is almost never the statin itself. Instead, the culprits tend to be the same forces that drove lipid levels up in the first place: diet, body weight, insulin resistance, genetics, other medications, and sometimes conditions that have nothing to do with cholesterol at all.

How Statins Affect Triglycerides

Statins were designed to lower LDL cholesterol, and that remains their headline job. But clinical trials have shown they also bring down triglyceride-rich particles, specifically the very-low-density lipoprotein (VLDL) particles that carry most circulating triglycerides.¹ Researchers initially found this surprising, because the main way statins work is by increasing the number of LDL receptors on liver cells, and those receptors primarily clear LDL, not VLDL. The triglyceride-lowering effect appears to come from a secondary consequence of the same process: when the liver ramps up receptor activity, it also pulls in some VLDL remnants, and it produces fewer VLDL particles to begin with because cholesterol synthesis is suppressed.

In practice, the triglyceride drop from a statin is real but modest compared to its LDL-lowering punch. A head-to-head comparison of four different statins found that all of them reduced triglyceride levels effectively.² If your triglycerides were borderline before starting a statin, the drug alone may nudge them into the normal range. If they were very high to begin with, a statin will likely improve them but probably not fix the problem entirely.

Do Some Statins Lower Triglycerides More Than Others

Yes, though the differences are not dramatic. Rosuvastatin and atorvastatin, the two most commonly prescribed high-intensity statins, have been compared repeatedly. A 2025 meta-analysis pooling data from multiple trials found that rosuvastatin lowered triglycerides by about 32 mg/dL on average, compared to roughly 25 mg/dL for atorvastatin.³ That gives rosuvastatin a slight edge in triglyceride reduction across the board.

Individual trials have been less consistent. One randomized trial of high-risk patients found the triglyceride effects of the two drugs were similar.⁴ Another dose-ranging comparison found no significant differences at most equivalent doses, except that atorvastatin at its highest dose (80 mg) produced a greater triglyceride drop than the corresponding rosuvastatin dose.⁵ The practical takeaway: switching from one statin to another might shave off a few extra triglyceride points, but it is unlikely to be the solution if your levels are significantly elevated.

Why Triglycerides Stay High on a Statin

When someone’s triglycerides remain elevated despite statin therapy, the statin is almost certainly still doing its part. The issue is that other forces are pushing triglycerides up faster than the statin can pull them down. The most common drivers fall into a few categories.

Diet, Alcohol, and Body Weight

Triglycerides respond quickly and directly to what you eat and drink. Refined carbohydrates and sugars are among the most potent dietary triggers, because the liver converts excess carbohydrate into triglyceride-rich VLDL particles. Alcohol has a similar effect, and even moderate drinking can raise triglycerides measurably in some people. Obesity is one of the most common secondary causes of high triglycerides, alongside uncontrolled diabetes and alcohol misuse.⁶ If someone starts a statin but doesn’t change the dietary and lifestyle patterns that elevated their triglycerides in the first place, the statin’s modest triglyceride-lowering effect gets overwhelmed.

Insulin Resistance and Diabetes

Insulin resistance is one of the most powerful drivers of high triglycerides, and it operates through a specific mechanism. When cells become resistant to insulin, an enzyme called lipoprotein lipase (which normally breaks down triglyceride-rich particles in the bloodstream) becomes less active.⁷ At the same time, the liver ramps up production of VLDL. The result is a double hit: more triglycerides being made and fewer being cleared. People with type 2 diabetes or prediabetes often have triglyceride levels that remain elevated even with statin therapy, and improving blood sugar control can bring triglycerides down as much as or more than adding a second lipid drug.

Genetics

Some people are genetically predisposed to high triglycerides, and no amount of lifestyle adjustment or statin therapy will fully normalize their levels. Researchers have identified several genes involved in triglyceride metabolism, including those controlling lipoprotein lipase and its support proteins. In a study of over 500 patients with severe hypertriglyceridemia, about one in seven carried a rare genetic variant in one of these genes, compared to fewer than one in 25 among people with normal lipid levels.⁸ Most cases of genetically driven high triglycerides are not caused by a single dramatic mutation, though. They result from an accumulation of many common gene variants that each nudge triglyceride levels a bit higher, combined with lifestyle and metabolic factors that pile on top.

Other Medications and Medical Conditions

A number of commonly used medications raise triglycerides as a side effect. Beta-blockers, thiazide diuretics, oral estrogens, retinoids (like isotretinoin), some antipsychotics, and certain immunosuppressants can all push levels up. If you started one of these around the same time you started a statin, the triglyceride-raising effect of the new drug can mask the statin’s triglyceride-lowering effect. Underlying conditions beyond diabetes also play a role. Hypothyroidism slows the clearance of triglyceride-rich particles. Chronic kidney disease is associated with high triglyceride rates across disease stages; one study found roughly a third of patients at each stage of kidney disease had triglycerides above 200 mg/dL.⁹ Nephrotic syndrome, liver disease, and certain autoimmune conditions can also contribute.

Triglyceride Measurements Are Noisier Than You Think

Before assuming your triglycerides are genuinely elevated, it helps to understand how much natural variation exists in these numbers. Triglyceride levels bounce around far more than cholesterol does. The biological variability in triglycerides averages around 20-23%, meaning that if your “true” fasting level is 150 mg/dL, a perfectly accurate test might return anything from roughly 115 to 185 on different days, depending on recent meals, stress, exercise, sleep, and dozens of other factors.¹⁰ Some individuals see variability as high as 40%.¹¹ For comparison, total cholesterol varies by only about 6% from test to test.

Fasting is supposed to reduce some of this noise, which is why doctors traditionally asked you to fast for 9 to 12 hours before a lipid panel. But in recent years, many guidelines have moved toward accepting non-fasting samples, since they are more convenient and the difference is manageable for screening purposes. One study found that non-fasting triglyceride values ran about 16% higher than fasting values, and this gap was similar whether or not the patient was taking a statin.¹² So if your “elevated” reading came from a non-fasting draw, a fasting recheck might bring the number down, though it also might not. The point is that a single triglyceride reading is a snapshot, not a settled verdict. Trends over multiple tests matter far more.

When the Lab Result Itself Is Wrong

In rare cases, the triglyceride number on your lab report is genuinely inaccurate. Most commercial lab assays measure triglycerides indirectly: they break triglyceride molecules down into glycerol and fatty acids, then measure the glycerol. This works fine for the vast majority of patients. But if free glycerol is elevated in your blood for other reasons, the test will overcount and report a falsely high triglyceride level. This is called pseudohypertriglyceridemia.¹³

Known causes include glycerol kinase deficiency (a genetic condition where glycerol builds up because the body cannot process it normally) and even glycerol-contaminated blood collection tubes.¹⁴ Pseudohypertriglyceridemia is uncommon, but it is worth considering when someone has very high triglyceride readings that do not match the rest of their metabolic profile, especially if those readings do not respond to any treatment.

What Happens When You Stop Taking a Statin

One scenario that can cause a surprising spike in triglycerides is missing doses or stopping the statin entirely. Statins have short half-lives, and their effects begin to wear off within days. A study tracking patients who discontinued statin therapy found that triglyceride levels jumped by about 17% within four days of stopping. By one to two weeks, they had risen roughly 34% above the levels measured while on the statin.¹⁵ LDL cholesterol rose even more dramatically, climbing about 79% above treated levels. Once patients restarted the statin, both triglycerides and cholesterol returned to baseline within about 20 days.

This matters because inconsistent adherence is extremely common with statins. If you miss doses in the week before a blood draw, the lab work will show higher triglycerides and cholesterol than your “on-treatment” levels, and it can look like the drugs are not working. If your doctor sees an unexpected rise in your lipid numbers, an honest conversation about missed doses is worth having before adding new medications.

Why Elevated Triglycerides on a Statin Still Matter

For years, the medical community debated whether triglycerides independently cause cardiovascular problems or are just a marker of other metabolic trouble. The evidence now suggests they contribute real risk on their own, even in people whose LDL cholesterol is well controlled by a statin. A large real-world study of statin-treated patients found that those with triglycerides above 200 mg/dL had a roughly 35% higher rate of major cardiovascular events compared to statin-treated patients with lower triglycerides.¹⁶ The risk was spread across heart attacks, strokes, and the need for procedures to reopen blocked arteries.

A separate analysis of a large healthcare system found a similar pattern: statin-treated patients with triglycerides at 150 mg/dL or above had a higher risk of cardiovascular events, though, in an interesting wrinkle, they actually had a slightly lower risk of death from any cause.¹⁷ That paradox may reflect confounding factors like weight loss from illness, where low triglycerides can be a sign of poor health rather than good metabolic control. The cardiovascular-event finding, though, was consistent: high triglycerides on a statin represent leftover risk that the statin alone has not eliminated.

Add-On Treatments for Stubborn Triglycerides

When lifestyle changes and statin therapy together are not enough to bring triglycerides into range, a few additional drug options exist. The choice depends on how high the levels are and what the treatment goal is.

Prescription Omega-3 Fatty Acids

High-dose prescription omega-3 fatty acids (not the fish oil capsules from the supplement aisle) are one of the most studied add-on therapies. An American Heart Association science advisory concluded that prescription omega-3s containing EPA and DHA, at a dose of 4 grams per day, are effective for lowering triglycerides either alone or combined with a statin.¹⁸ A meta-analysis of randomized trials confirmed that combining omega-3s with statins produced meaningful additional triglyceride reductions beyond what the statin alone achieved.¹⁹

The cardiovascular outcome story for omega-3s has focused on one specific formulation. The REDUCE-IT trial tested high-dose icosapent ethyl (a purified EPA-only product) in statin-treated patients with elevated triglycerides and either established cardiovascular disease or high risk of it. The trial showed a clear reduction in cardiovascular events, leading to widespread adoption of the drug in high-risk patients.²⁰ Whether that benefit was entirely due to triglyceride lowering or partly to other anti-inflammatory properties of EPA remains an active area of debate. Still, for statin-treated patients with persistent mild-to-moderate triglyceride elevation and elevated cardiovascular risk, this is one of the better-supported treatment options available.

Fibrates

Fibrates like fenofibrate have been used for decades to lower triglycerides. They work through a different mechanism than statins, activating a receptor that ramps up the breakdown of triglyceride-rich particles. Combining a fibrate with a statin produces significantly greater triglyceride reduction and HDL improvement compared with a statin alone.²¹ In one randomized trial, patients whose triglycerides remained high despite statin therapy saw their average levels drop from about 270 mg/dL to around 146 mg/dL after eight weeks of adding fenofibrate, while the group continuing statin alone saw no change.²²

There is an important caveat about safety. A meta-analysis found that while the statin-fibrate combination was more effective for lipid improvement, statin therapy alone was associated with fewer adverse events, including liver-related and kidney-related problems.²³ The combination is generally considered safe, but it does require monitoring. An older combination, gemfibrozil with a statin, carried a meaningful risk of muscle damage and is largely avoided today. Fenofibrate is the fibrate of choice for pairing with a statin.

Newer Targets on the Horizon

For patients whose triglycerides resist conventional therapy, a new generation of drugs targeting specific proteins in triglyceride metabolism is emerging. Two of the most promising targets are ANGPTL3 and apolipoprotein C-III (apoC-III). Both of these proteins normally slow down the clearance of triglyceride-rich particles from the blood. Drugs that block them allow the body to clear those particles faster. Early data suggest these inhibitors are potent triglyceride-lowering agents, with apoC-III inhibitors showing possibly even greater effect.²⁴ These agents are being developed for severe cases, including people with genetic conditions causing extreme triglyceride elevation who face repeated episodes of pancreatitis. They are also being explored for reducing leftover cardiovascular risk in patients already on statins and other standard therapies.

The Statin-and-Calories Problem

There is one indirect way statins can contribute to higher triglycerides, and it has nothing to do with the drug’s pharmacology. Some evidence suggests that people who start a statin gradually increase their calorie and fat intake over the years that follow, possibly because the psychological safety net of “taking a pill for it” reduces the motivation to watch what they eat. This behavioral shift can raise triglycerides, body weight, and insulin resistance. The statin is still lowering lipid levels compared to what they would be without it, but the lifestyle changes are pushing everything back up. If you have been on a statin for several years and notice your triglycerides creeping upward, it is worth an honest look at whether your eating and activity habits have drifted since you started the medication.